Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$477.37 USD
+5.37 (1.14%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $478.39 +1.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$477.37 USD
+5.37 (1.14%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $478.39 +1.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
The Zacks Analyst Blog Highlights UnitedHealth Group, Danaher, Wells Fargo, Vertex Pharmaceuticals and Canadian Pacific Railway
by Zacks Equity Research
UnitedHealth Group, Danaher, Wells Fargo, Vertex Pharmaceuticals and Canadian Pacific Railway have been included in this Analyst Blog.
Q1 Scorecard and Analyst Reports for UnitedHealth, Danaher & Wells Fargo
by Sheraz Mian
Today's Research Daily features Q1 earnings season scorecard and fresh reports on UnitedHealth(UNH), Danaher (DHR), Wells Fargo (WFC) & others.
J&J (JNJ) Beats on Q1 Earnings, Suspends COVID Jab Sales View
by Zacks Equity Research
J&J (JNJ) reports mixed first-quarter results. It beats estimates for earnings but misses the same for sales. It cuts full-year outlook.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Vertex Pharmaceuticals (VRTX) Stock Moves -1.02%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $287.97, marking a -1.02% move from the previous day.
The Zacks Analyst Blog Highlights Splunk, Vertex Pharmaceuticals, Henry Schein, Jack Henry & Associates, and Check Point Software Technologies
by Zacks Equity Research
Splunk, Vertex Pharmaceuticals, Henry Schein, Jack Henry & Associates, and Check Point Software Technologies are part of Top Analyst Blog.
Top 5 High-Flying Nasdaq Stocks Amid Index's YTD Meltdown
by Nalak Das
We have narrowed our search to five Nasdaq listed stocks that have witnessed double-digit rally year to date. These are: VRTX, SPLK, HSIC, CHKP and JKHY.
The Zacks Analyst Blog Highlights Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.
Biotech Stock Roundup: VIR Down on Regulatory News, BMY Offers Updates & More
by Zacks Equity Research
Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.
Vertex (VRTX) Stock Rallies 27% in a Year: What Lies Ahead?
by Zacks Equity Research
In 2022, Vertex (VRTX) expects continued revenue growth as there are more than 25,000 patients who are addressable with Vertex's CF therapies.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $269.96 in the latest trading session, marking a +0.49% move from the prior day.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $268.64, moving +0.94% from the previous trading session.
Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies
by Zacks Equity Research
Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.
Novartis (NVS) Beovu Gets Label Expansion for DME in EU
by Zacks Equity Research
Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.
Zacks Investment Ideas feature highlights: Vertex Pharmaceuticals
by Zacks Equity Research
Vertex Pharmaceuticals has been highlighted in this Investment Ideas article.
Why April Has the Bulls Beaming
by Bryan Hayes
April is the best month for the Dow since 1950 - averaging about a 2% gain.
Biogen (BIIB) Plans to Start Aduhelm Confirmatory Study in May
by Zacks Equity Research
Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.
IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi
by Zacks Equity Research
IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.
Roche (RHHBY) Late-Stage Study for ES-SCLC Fails to Meet Goal
by Zacks Equity Research
Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint of progression-free survival.
Pfizer (PFE) 2nd Ulcerative Colitis Study on Etrasimod Succeeds
by Zacks Equity Research
Pfizer's (PFE) ELEVATE UC 52 is the second phase III study on etrasimod for ulcerative colitis to have met primary and key secondary endpoints.
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $257.98, moving +0.88% from the previous trading session.
Prothena (PRTA) IND Application Gets FDA Clearance for AD
by Zacks Equity Research
Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.
Bristol Myers (BMY) Application for Opdivo With Chemo Validated
by Zacks Equity Research
Bristol Myers (BMY) type II variation application for Opdivo in combination with chemotherapy for the neoadjuvant treatment of patients with non-small cell lung cancer gets EMA validation.
Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion
by Zacks Equity Research
The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.
Axsome (AXSM) to Acquire Jazz's Sleep Disorder Drug, Sunosi
by Zacks Equity Research
Axsome (AXSM) inks an agreement with Jazz Pharmaceuticals to acquire the latter's new sleep disorder drug, Sunosi. The transaction is expected to close in the second quarter of 2022.